Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The purpose of this study was to determine the effects of bisphosphonates periprosthetic BMD in THA patients as a function of stem design. Specifically, the goals were to determine if bisphosphonates as a group could significantly inhibit periprosthetic bone loss, time needed to see an effect, if one drug was more effective than the others, and if there was a difference due to stem design or cement. Thirteen articles met the inclusion criteria. Overall, groups treated with bisphosphonate therapy preserved significantly more BMD than the control groups as early as six months postoperatively, and orally delivered bisphosphonates were most effective. Furthermore, the biggest differences were in patients with non-cemented stems, and of those, the largest differences were seen in patients with fully coated CoCr stems.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.arth.2014.01.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Efficacy of Stem Cell Therapy in Neurotraumatic and Neurodegenerative Conditions: A Comparative Review.
Tissue Eng Regen Med
September 2025
Department of Biomedical Science, Catholic Kwandong University, 24 Beomil-ro 579beon-gil, Gangneung-si, Gangwon-do, South Korea.
Background: Neurotraumatic conditions, such as spinal cord injury, brain injury, and neurodegenerative conditions, such as amyotrophic lateral sclerosis, pose a challenge to the field of rehabilitation for its complexity and nuances in management. For decades, the use of cell therapy in treatment of neurorehabilitation conditions have been explored to complement the current, mainstay treatment options; however, a consensus for standardization of the cell therapy and its efficacy has not been reached in the medical community. This study aims to provide a comparative review on the very topic of cell therapy use in neurorehabilitation conditions in an attempt to bridge the gap in knowledge.
View Article and Find Full Text PDFBiomimetic nanocarriers for the therapy and management of intestinal inflammations.
Int J Pharm X
December 2025
Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector-125, Noida 201313, India.
Intestinal inflammation particularly inflammatory bowel disease poses significant clinical challenges due to its chronic nature, limited treatment efficacy and adverse effects of conventional therapies like corticosteroids and biologics. Biomimetic nanocarriers have emerged as a transformative strategy to overcome these limitations by leveraging natural cell membranes for targeted drug delivery. This review critically examines the application of biomimetic nanocarriers as precision therapeutics for intestinal inflammation.
View Article and Find Full Text PDFIdentification of critical process parameters and quality attributes for bioreactor-based expansion of human MSCs.
Front Bioeng Biotechnol
August 2025
Department Bio-Adaptive production, Fraunhofer Institute for Production Technology (FHG), Aachen, Germany.
Mesenchymal stem/stromal cells (MSCs) have been identified as a promising therapeutic option for osteoarthritis, graft vs. host disease and cardiovascular diseases, among others. For widespread application of these therapies, robust and scaled manufacturing processes are required that reliably yield high amounts of high quality MSCs.
View Article and Find Full Text PDFOptimization of Mesoporous Carbon Adsorbents from Sucrose and Aerosil 380 Hydrophilic Silica by Hard Templating.
ACS Omega
September 2025
Federal University of TechnologyParanáUTFPR, Graduate Program in Chemical and Biotechnological Processes (PPGQB), Rua Cristo Rei, 19, Vila Becker, Toledo 85902-490, Paraná, Brazil.
Mesoporous carbon materials were synthesized by using sucrose as a carbon source and hydrophilic Aerosil 380 as a hard template. A two-stage optimization process based on the response surface methodology using a central composite design (RSM-CCD) was employed to enhance the adsorption performance of the material for the crystal violet (CV) dye. The first stage of optimization yielded a maximum adsorption capacity of 155.
View Article and Find Full Text PDFHematopoietic stem cell gene therapy for the treatment of X-linked agammaglobulinemia.
Mol Ther Methods Clin Dev
September 2025
Molecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.
X-linked agammaglobulinemia (XLA) is a rare inborn error of immunity caused by loss-of-function mutations in the gene encoding Bruton's tyrosine kinase (BTK). XLA patients lack mature B cells and have negligible antibody levels, leaving them susceptible to recurrent bacterial and chronic viral infections. Autologous hematopoietic stem cell gene therapy with gene-corrected HSC may serve as a promising treatment of XLA; this therapy would provide a one-time cure and would replace lifelong immunoglobulin replacement therapy.
View Article and Find Full Text PDF